The Anglo-Swedish pharmaceutical group AstraZeneca announced on Tuesday that it had suffered a setback in the development of a treatment for the coronavirus, the effectiveness of which on people exposed to the virus has not been proven. by antibody, the code name of which is AZD7442 and which is intended to both prevent and treat the disease.
World, June 15, 2021.- Another setback for AstraZeneca. After many countries have partially or completely turned away from its anti-covid vaccine, the Anglo-Swedish pharmaceutical group announced on Tuesday that the treatment against the coronavirus it is currently developing has not proven its effectiveness on exposed people to the virus.
“The trial did not achieve the main goal of preventing symptomatic Covid-19 cases after exposure” to the virus, AstraZeneca explains in a statement.
Trials are continuing to evaluate the remedy in patients before exposure to the virus, and for those who have developed severe forms, the document said.
Belly Info (VBI)
–
